Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals

Pharmazie

Volumn 61, Issue 10, 2006, Pages 878-886

  Schüssel, Katrin ^a,b   Schulz, Martin ^a  

^a German Institute for Drug Use Evaluation (GIDE)   (Germany)

^b ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACEMETACIN; ANALGESIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ARTHROTEC; CELECOXIB; CENTRAL STIMULANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; ETORICOXIB; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VALDECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MARKETING; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GERMANY; GOUT; HEALTH INSURANCE; HEART INFARCTION; HUMAN; MEDICAL SPECIALIST; OSTEOARTHRITIS; PATIENT SAFETY; PHARMACY; PRESCRIPTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF MEDICATION; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ANTI-ULCER AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; GERMANY; HUMANS; INSURANCE, HEALTH; PHARMACISTS; PRESCRIPTIONS, DRUG;

EID: 33750361633     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. ABDATA (ed.) (2003-2005) ABDA Datenbank and ABDA Artikelstamm, bimonthly update, ABDATA Pharma Daten Service, Eschborn, Germany.
2. Aldington S, Shirtcliffe P, Weatherall M, Beasley R (2005) Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 118: U1684.
3. Arzneimittelkommission der Deutschen Ärzteschaft (ed.) (2001) Degenerative Gelenkerkrankungen. Arzneiverordnung in der Praxis - Therapie-empfehlungen, Cologne, Germany.
4. Arzneimittelkommission der Deutschen Ärzteschaft (2006) Psychiatrische Störungen unter Metamizol (UAW-News - International). Dtsch Ärztebl 103: A 499.
5. Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, Geba GP (2004) Pain management in osteoarthritis: a focus on onset of efficacy-a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 5: 511-520.
6. BfArM Bundesinstitut für Arzneimittel und Medizinprodukte (2004) Pressemitteilungen, Bonn, Germany. http://www.bfarm.de/de/Presse/mitteil_2004/ index.php accessed on January 27, 2006.
7. BfArM Bundesinstitut für Arzneimittel und Medizinprodukte (2005) Pressemitteilungen, Bonn, Germany. http://www.bfarm.de/de/Presse/mitteil_2005/ index.php accessed on January 27, 2006.
8. Bjorkman DJ (1999) Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 107: 3S-8S.
9. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528.
10. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P (2004) The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 63: 1028-1034.
11. Bouvy M, Cheung K-C (2005) Follow-up of rofecoxib-users after market withdrawal. 34th European Symposium on Clinical Pharmacy, ESCP, October 26-29, 2005, Amsterdam.
12. Bouvy M, Kruijtbosch M, Cusell-Borgh M (2005) NSAIDS: are gastrointestinal and cardiovascular risks considered? 34th European Symposium on Clinical Pharmacy, ESCP, October 26-29, 2005, Amsterdam.
13. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
14. Bundesministerium für Gesundheit (2006) Mitgliederstatistik KM 6, Berlin, Germany. http://www.bmg.bund.de/cln_040/nn_601098/SharedDocs/Download/ DE/ Datenbanken-Statistiken/Statistiken-Gesundheit/Gesetzliche- Krankenversicherung/Mitglieder-und-Versicherte/2005-km6-lang-xls,templateld=raw, property=publicationFile.xls/2005-km6-lang-xls.xls accessed on March 24, 2006.
15. Bundesministerium für Gesundheit und Soziale Sicherung (2005) Gesetzliche Krankenversicherung - Mitglieder und mitversicherte Angehörige nach Altersgruppen 1992 bis 2004, Berlin, Germany. http://www.bmg.bund.de/ cln_040/nn_601098/SharedDocs/Download/DE/ Datenbanken-Statistiken/Statistiken- Gesundheit/Gesetzliche-Krankenversicherung/Mitglieder-und-Versicherte/ Versicherte-1992-2004-pdf-6849, templated=raw,property=publicationFile.pdf/ Versicherte-1992-2004-pdf-6849.pdf accessed on March 24, 2006.
16. de Abajo FJ, Rodriguez LA, Montero D (1999) Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 319: 1106-1109.
17. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT (2003) Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 55: 591-595.
18. EMEA European Agency for the Evaluation of Medicinal Products (2005) CHMP Committee for Medicinal Products for Human Use, London, United Kingdom. Press releause: European Medicines Agency update on non-selective NSAIDs, October 17, 2005. http://www.emea.eu.int/pdfs/ human/press/pr/29896405en.pdf accessed on January 27, 2006.
19. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verbeugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684.
20. FDA Food and Drug Adminsitration (2004) Center for Drug Evaluation and Research, USA. Vioxx (rofecoxib) questions and answers. http://www.fda.gov/cder/ drug/infopage/vioxx/vioxxQA.htm accessed on January 27, 2006.
21. Pick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 163: 2716-2724.
22. Gemeinsamer Bundesausschuss: Gesetzliche Verordnungsausschlüsse bei der Arzneimittelversorgung und zugelassene Ausnahmen, Bundesanzeiger Nr. 247, 17236, 2005.
23. Grossmann A, Kampmann C (2005) Verordnungs- und Umsatzentwicklung der Wirkstoffgruppe COX-2-Hemmer im BKK-System von Januar 2003 bis Juni 2005. 12 Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung GAA, November 31-December 1, 2005, Dresden, Germany.
24. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlen SE, Szczeklik A, Murray JJ, Dahlen B (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111: 1116-1121.
25. Herdegen T, Fauler J (2006) Drug safety of NSAIDs and COX-2 inhibitors. Med Monatsschr Pharm 29: 122-128.
26. Herings RM, Goettsch WG (2004) Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 38: 760-763.
27. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366.
28. Jones SC (2005) Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 39: 1249-1259.
29. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 53: 1679-1685.
30. Konstantinopoulos PA, Lehmann DF (2005) The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 45: 742-750.
31. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ (2004) A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 51: 746-754.
32. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363: 1751-1756.
33. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277.
34. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693-11697.
35. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
36. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005a) Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 94: 34-38.
37. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005b) Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 95: 154-158.
38. Schneider M, Lelgemann M, Abholz H-H, Caratti R, Flügge C, Jäniche H, Kunz R, Krüger K, Rehart S und Specker C (ed.) (2004) Management der frühen rheumatoiden Arthritis. Klinische Leitlinie im Auftrag der Deutschen Gesellschaft für Rheumatologie
39. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674.
40. Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP (2005) Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 32: 1093-1105.
41. Schoenhofer P, Offerhaus L, Herxheimer A (2003) Dipyrone and agranulocytosis: what is the risk? Lancet 361: 968-969.
42. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA (2004) Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 43: 467-478.
43. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA (2004) Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J Manag Care 10: 742-750.
44. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255.
45. Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105: 31S-38S.
46. Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56: 18-24.
47. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
48. Sozialgesetzbuch SGB V (2005). http://gesetze.bmas.bund.de/Gesetze/ gesetze.htm accessed on March 24, 2006.
49. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31: 219-225.
50. Tavares IA, Bennett A (1993) Acemetacin and indomethacin: differential inhibition of constitutive and inducible cyclo-oxygenases in human gastric mucosa and leucocytes. Int J Tissue React 15: 49-53.
51. The International Agranulocytosis and Aplastic Anemia Study Group (1986) Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256: 1749-1757.
52. WHO Collaborating Centre for Drug Statistics Methodology (2006) ATC/DDD Index 2006. http://www.whocc.no/atcddd/ accessed on January 27, 2006.
53. WIdO Wissenschaftliches Institut der Ortskrankenkassen and DIMDI Deutsches Institut für medizinische Dokumentation und Informatik (ed.) (2006): Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen - amtliche deutsche Fassung, Cologne, Germany. http://wido.de/ fileadmin/wido/downloads/pdf_arzneimittel/wido_arz_amtl_atc-index_0106.pdf accessed January 27, 2006.